2 天前 - … global response to the COVID-19 pandemic. To date, 3 small-molecule antiviral
drugs have been … [2], MOV remains an important option for certain patients because it is orally …

4 天前 - … severe acute respiratory syndrome coronavirus 2 (SARS‐… In contrast, oral clinical
drugs targeting viral protease and … and LTV exhibited comparable antiviral activity as NTV and …

4 天前 - … coronavirus disease 2019 (COVID-19) condition (PCC). Patients with mild-to-moderate
COVID-19 … of symptom onset; received 5-day oral ensitrelvir 125 mg (375 mg on day 1), …

11 天前 - … cytokines for the antiviral response against epithelium-… A general overview of the
COVID-19 pandemic discussed … of Paxlovid, the first orally available COVID-19 drug [10]. The …

12 天前 - … oral therapies for COVID-19 with low potential for drug–drug interactions.
Obeldesivir is an orally … The in vitro antiviral activities of nucleoside prodrugs remdesivir and …

15 天前 - … Results: Four different antiviral agents that had been used in the treatment of
COVID-19 patients … It can be considered for inhalation and oral drug development. Generally, …

16 天前 - … Nirmatrelvir, a pivotal component of the oral antiviral Paxlovid for COVID-19,
targets the SARS-CoV-2 main protease (M pro ) as a covalent inhibitor. Here, we employed …

17 天前 - … for low utilization of COVID-19 oral antivirals during a period of … severe COVID-19
and determined whether perceived risk was associated with the use of COVID-19 oral antiviral …

19 天前 - … and effective oral antiviral therapeutic used for treatment of mild-to-moderate COVID-19.
… There is a lack of information on frequency of COVID-19 rebound after NM/r in routine …

20 天前 - … use of oral antiviral drugs and the risk of post covid-19 … to either COVID-19 or
post-acute COVID-19 syndrome (… 2023 when we searched for ‘COVID-19’. Trials with fewer than …